Marisa Wexler, MS, senior science writer —

For people with multiple sclerosis (MS), all forms of exercise are likely to be beneficial for physical fitness, but certain forms of exercise may be better than others at improving specific measures of fitness, according to a review of multiple clinical trials. Results suggest that resistance training — pushing…

Disease-associated inflammatory activity of microglia — a type of immune cell with a central role in the development of multiple sclerosis (MS) — is driven in part by molecular mechanisms that are activated when microglia try to clear the corpses of dead myelin-making cells. That’s according to a new…

People with relapsing multiple sclerosis (MS) who experienced disease activity while on oral therapies had less disease activity after switching to Kesimpta (ofatumumab), according to an analysis of data from the Phase 3 ARTIOS clinical trial. The patients previously were on Gilenya (fingolimod), or fumarate-based therapies such…

Microparticles that activate regulatory T-cells, or Tregs, an immune cell type with anti-inflammatory properties, reversed the accumulation of physical disability due to multiple sclerosis (MS) in a mouse model of the neurodegenerative disorder, a new study shows. Use of the novel strategy even cured some of the animals. “We…

Analyses of protein levels in the blood can be used to identify groups of multiple sclerosis (MS) patients with distinct clinical features, new research shows. Given the variability of symptoms among people with MS, such groupings could help to improve individualized care for patients, according to Octave, a…

Long-term treatment with vidofludimus calcium (IMU-838) has been tolerated well overall among people with relapsing-remitting MS (RRMS), new data from an extension study show. Findings were presented at the Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, in a poster titled “Assessment of Long-Term Safety…

The European Commission has approved Briumvi (ublituximab) for the treatment of adults with relapsing forms of multiple sclerosis (MS) who have active disease, as defined by clinical or imaging features. The approval, which covers all member states in the European Union, as well as Iceland, Norway, and Liechtenstein,…

The average rate of relapses for multiple sclerosis (MS) in the modern era is lower than it has been in decades past, according to a new analysis from the U.K. Scientists speculate the availability of new, more effective disease-modifying therapies may help explain why relapses appear to…

Treatment with the cannabis oral spray nabiximols helped to relieve spasticity — increased muscle stiffness and spasms common in people with multiple sclerosis (MS) — among participants in two MS clinical trials, according to the results of a new analysis. “In this analysis, nabiximols was shown to significantly…

Stem cell therapy is better than Gilenya (fingolimod) or Tysabri (natalizumab) at reducing relapse rates and easing disability for people with highly active relapsing-remitting multiple sclerosis (RRMS), a new analysis suggests. In contrast, findings suggest that the efficacy of stem cell therapy is not significantly different…

An updated snapshot of multiple sclerosis (MS) in the U.S. — provided by new population estimates from a study of insurance data — shows a greater prevalence of MS among white and Black people compared with other racial and ethnic groups. But overall, the neurodegenerative disorder has become more…

When the immune system launches an attack to fight off infection with the Epstein-Barr virus, immune cells can accidentally end up targeting a protein called CRYAB that’s normally expressed by healthy myelin-making cells in the brain, a study found. The findings provide further evidence that molecular similarities between distinct…

People with multiple sclerosis (MS) who have never received treatment with a disease-modifying therapy tend to have better long-term outcomes after stem cell transplant, according to a recent report from a center in Mexico. The findings suggest that stem cell therapy may be most beneficial when given…

A newly developed laboratory model using tadpoles can help determine the remyelinating potential of new multiple sclerosis (MS) therapies via specific changes in behavior and vision tests, a new study suggests. The model may help accelerate the discovery of potential MS remyelinating therapies, and reduce the use of resources…

Blood levels of the nerve damage marker NfL seem to spike to very high levels around times of disease activity in children with multiple sclerosis (MS), a new study reports. The findings support using NfL as a biomarker of disease activity, in the form of relapses or lesions, in…

Rehabilitation therapy that utilizes virtual reality can help to improve balance and reduce the fear of falling for people with multiple sclerosis (MS), a new analysis shows. “Our findings provide support to the use of [virtual reality-based therapy] to recover balance in neurological diseases such as MS,” researchers wrote.

Nearly half of the people with relapsing forms of multiple sclerosis (MS) treated early with Ocrevus (ocrelizumab) in Phase 3 clinical trials showed no evidence of disease activity after up to nine years on the therapy, data show. In contrast, about one-quarter of enrolled patients who started on…

More than 80% of patients with relapsing forms of multiple sclerosis (MS) given Kesimpta (ofatumumab) continuously for up to five years in a clinical trial did not have any documented worsening of disability over the duration of the treatment. That’s according to new data from the ongoing…

There was no evidence of multiple sclerosis (MS) disease activity for at least two years in patients who underwent an autologous hematopoietic stem cell transplant (aHSCT) at a center in Mexico. And by the most recent follow-up — a median of about seven years after the procedure —…

More than 90% of Black and Hispanic patients with multiple sclerosis (MS) treated with Ocrevus (ocrelizumab) in a Phase 4 clinical trial experienced no new relapse activity or sustained disability worsening after nearly one year, according to an interim analysis. However, more than half of these patients experienced…

Treatment with Aubagio (teriflunomide) significantly reduces the risk that adults with radiologically isolated syndrome (RIS) will develop symptoms of multiple sclerosis (MS), new clinical trial data show. This is the second trial showing that approved disease-modifying therapies can delay the development of MS in people who have…

Supplements with tauroursodeoxycholic acid (TUDCA) were generally well tolerated among people with progressive forms of multiple sclerosis (MS), according to findings from a small clinical trial. Results also showed that patients given TUDCA supplements had lower levels of certain inflammatory immune cells than those given a placebo, but no…

Use of the cell therapy MSC-NP failed to show a significant effect on overall disability scores among people with progressive forms of multiple sclerosis (MS), according to data from a Phase 2 clinical trial. Results, however, indicated that MSC-NP improved walking ability for people with more advanced disease —…

Damage to the myelin sheath, a hallmark feature of multiple sclerosis (MS), leads to increased levels of fatty molecules called VLCFAs, which are converted by brain cells into an inflammation-driving signaling molecule called S1P, a study suggests. The discovery of this novel molecular pathway may open up new avenues…

Most treatments for multiple sclerosis (MS) are not associated with an increased risk of complications during pregnancy, according to a new analysis. A few therapies were associated with slightly elevated rates of congenital abnormalities for babies exposed to treatment during pregnancy, but small sample sizes limit being able to…

People with secondary progressive multiple sclerosis (SPMS) seem to experience slower worsening of their disabilities than those with the primary progressive form of the disease (PPMS), a new study reports. However, SPMS patients tend to be older and have more advanced disability when they enter the progressive stage…

A novel formulation of ibudilast, delivered into the nose, was able to reduce inflammation and prevent nerve damage in a mouse model of multiple sclerosis (MS), a study found. The nasal formulation also improved regeneration of myelin, the protective sheath around nerve fibers that is progressively lost…

Scientists have developed new skin patches that could offer a more convenient and less painful way to administer antibody-based medicines to people with multiple sclerosis (MS) and other disorders. “The developed [skin] patch is minimally invasive, self-administrable, and designed to be fully embedded into the skin with a short…

Abnormal perceptions of discomfort and fatigue likely play a role in causing increased heat and cold sensitivity to extreme temperatures among people with multiple sclerosis (MS), a new study shows. However, the results suggest that MS does not generally affect how the body regulates its own temperature. “Our findings…

People with multiple sclerosis (MS) tend to accrue more medical costs after switching to infusible therapies Ocrevus (ocrelizumab), Tysabri (natalizumab), or Lemtrada (alemtuzumab), according to an analysis of data from commercially insured patients in the U.S. “The overall healthcare costs for MS patients increased a lot…